Bing

SEARCH HISTORY

Healthcare stocks declined 0.5% on Wall Street on Monday. More broadly, the Dow Jones Industrial Average fell 1.8%, the Nasdaq was down 1.5% and the S&P 500 fell 1.8%. Some of the biggest gainers among healthcare stocks include …
Investor Place · 1/6/2015
The past year hasn't been the kindest to NPS Pharmaceuticals' (NASDAQ: NPSP.DL ) shareholders, with the stock vastly underperforming the broader market and its peers. Yet, take off your short-term blinders and examine NPS Pharmaceuticals' …
The Motley Fool · BySean Williams · 10/7/2014
NEW YORK (TheStreet) -- NPS Pharmaceuticals (NPSP) shares are up 8.2% to $45.36 on heavy volume in early market trading today after the company agreed to be bought by Britain's Shire plc (SHPG) yesterday for $5.2 billion. The purchase price …
The Street · 1/12/2015
More from Bing News
NPS Pharmaceuticals, Inc. (NPSP) was a big mover last session, as its shares rose almost 14% on the day. This reverses the downtrend for the company since May 5, as the stock is now down nearly 4%. In the last 30 days, the company witnessed three …
Yahoo Finance · 5/12/2014
as there has been some decidedly negative earnings estimate revisions in NPS Pharmaceuticals' stock as of late. This is especially true when investors dive into some of these revisions in order to get a better picture of NPSP's prospects for the near term.
Benzinga · 1/7/2015
They are currently developing Natpara, a drug to be used to treat adult hypoparathyroidism, which affects 1% of the general population. NPSP data by YCharts The stock is down 6.36% YTD due to indecision regarding FDA approval of Natpara, though bullish ...
Seeking Alpha · 11/7/2014
Acquisitions and deals continue to be in focus with yet another pharma company announcing its intention to acquire a biotech company. Meanwhile, interest in the immuno-oncology area shows no signs of slowing down with another deal being announced.
ZACKS · 1/14/2015
NPSP) in an attempt to expand its reach in rare diseases such as gastrointestinal and endocrine disorders, Bloomberg reports. Rumors that Shire is weighing a bid for NPS sent the biotech’s stock soaring 18.5% to $36.10 yesterday. The stock is …
bidnessetc.com · 12/18/2014
The stock closed Friday at $33.28 a share. NPS Pharmaceuticals Inc. (NASDAQ: NPSP) CEO Francois Nader told Wall Street analysts to expect an FDA advisory panel to be held for its leading drug candidate Natpara before the Prescription Drug User …
24/7 Wall ST · 10/20/2014
Among the companies with shares expected to actively trade in Monday’s session are NPS Pharmaceuticals Inc., Foundation Medicine Inc. and MWI Veterinary Supply Inc. Shire PLC is buying NPS Pharmaceuticals, a maker of treatments for rare …
The Wall Street Journal · 1/12/2015